BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10875429)

  • 1. The rationale for long-term prophylaxis of venous thromboembolism.
    Agnelli G; Mancini GB; Biagini D
    Orthopedics; 2000 Jun; 23(6 Suppl):s643-6. PubMed ID: 10875429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.
    Colwell C; Mouret P
    Semin Vasc Med; 2005 Aug; 5(3):266-75. PubMed ID: 16123914
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Building effective prophylaxis of deep vein thrombosis in the outpatient setting.
    Agnelli G; Taliani MR; Verso M
    Blood Coagul Fibrinolysis; 1999 Aug; 10 Suppl 2():S29-35. PubMed ID: 10493228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-duration low-molecular-weight heparin prophylaxis following total joint arthroplasty.
    Whang PG; Lieberman JR
    Am J Orthop (Belle Mead NJ); 2002 Sep; 31(9 Suppl):31-6. PubMed ID: 12349893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of venous thromboembolic disease. The impact of low-molecular-weight heparin.
    Tapson VF; Hull RD
    Clin Chest Med; 1995 Jun; 16(2):281-94. PubMed ID: 7656540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?
    Kamphuisen PW; Agnelli G
    Thromb Res; 2007; 119(3):265-74. PubMed ID: 16674999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thromboembolic disease in surgery for malignancy-rationale for prolonged thromboprophylaxis.
    Khushal A; Quinlan D; Alikhan R; Gardner J; Bailey C; Cohen A
    Semin Thromb Hemost; 2002 Dec; 28(6):569-76. PubMed ID: 12536350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? A cost-effectiveness analysis.
    Sarasin FP; Bounameaux H
    Thromb Haemost; 2002 Apr; 87(4):586-92. PubMed ID: 12008939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inpatient and outpatient occurrence of deep vein thrombosis and pulmonary embolism and thromboprophylaxis following selected at-risk surgeries.
    Amin AN; Lin J; Thompson S; Wiederkehr D
    Ann Pharmacother; 2011 Sep; 45(9):1045-52. PubMed ID: 21862717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of venous thromboembolism in high-risk surgical and medical patients.
    Prandoni P; Sabbion P; Tanduo C; Errigo G; Zanon E; Bernardi E
    Semin Vasc Med; 2001; 1(1):61-70. PubMed ID: 15199515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic and practical aspects of thromboprophylaxis with unfractionated and low-molecular-weight heparins in hospitalized medical patients.
    Pineo GF; Hull RD
    Clin Appl Thromb Hemost; 2009 Oct; 15(5):489-500. PubMed ID: 19520676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
    Abad JI; Gómez-Outes A; Martínez-González J; Rocha E;
    Arch Orthop Trauma Surg; 2007 Oct; 127(8):665-70. PubMed ID: 17089172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of low molecular weight heparins for the prevention of postoperative venous thromboembolism in general surgery. A survey of practice in the United States.
    Caprini JA; Arcelus J; Sehgal LR; Cohen EB; Reyna JJ
    Int Angiol; 2002 Mar; 21(1):78-85. PubMed ID: 11941278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
    Míka P; Behounek J; Skoták M; Nevsímal L
    Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of anticoagulant prophylaxis to prevent venous thromboembolism in acutely ill medical inpatients: a meta-analysis.
    Själander A; Jansson JH; Bergqvist D; Eriksson H; Carlberg B; Svensson P
    J Intern Med; 2008 Jan; 263(1):52-60. PubMed ID: 18088252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review of the risks and benefits of differing prophylaxis regimens for the treatment of deep venous thrombosis and pulmonary embolism in neurosurgery.
    Epstein NE
    Surg Neurol; 2005 Oct; 64(4):295-301; discussion 302. PubMed ID: 16181995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.